Inactive Instrument

Enzymotec Ltd.

ENZY

IL0011296188

Enzymotec Ltd. Reaffirms Earnings Guidance for the Fiscal 2016

May 19, 2016 at 08:09 am

Enzymotec Ltd. reaffirmed earnings guidance for the fiscal 2016. The company reaffirmed its fiscal 2016 guidance of non-GAAP EPS of $0.25 - $0.30 on revenue of $56 million - $64 million.

Latest news about Enzymotec Ltd.

Aker Biomarine Antarctic AS acquired Krill Oil Business of Enzymotec Ltd. for $26.4 million.	18-01-16	CI
Enzymotec Ltd.(NasdaqGS:ENZY) dropped from NASDAQ Composite Index	18-01-11	CI
Frutarom Ltd. completed the acquisition of the remaining 81.3% stake in Enzymotec Ltd. from Paulson & Co. Inc. and others for approximately $230 million.	18-01-10	CI
Enzymotec Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-15	CI
Transcript : Enzymotec Ltd., Frutarom Industries Ltd. - M&A Call	17-10-30
Enzymotec Ltd. Announces Signed A Definitive Agreement with Frutarom Industries Ltd	17-10-30	CI
Enzymotec Ltd.(NasdaqGS:ENZY) dropped from S&P Global BMI Index	17-09-18	CI
Enzymotec Ltd. acquired five nutritional supplements from Union Springs Healthcare, LLC for $27.9 million.	17-08-29	CI
Frutarom Ltd. acquired an additional 9.2% stake in Enzymotec Ltd. from Paulson & Co. Inc. for $24.2 million.	17-08-23	CI
Frutarom Industries Ltd. made an offer to acquire the remaining 81.3% stake in Enzymotec Ltd. from Paulson & Co. Inc. and others for approximately $220 million.	17-08-23	CI
Enzymotec Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-08-16	CI
Enzymotec Ltd. Appoints Dror Israel as Vice President and Chief Financial Officer, Effective August 7, 2017	17-07-28	CI
Oren Bryan to Step Down as Vice President and Chief Financial Officer of Enzymotec Ltd	17-06-28	CI
Enzymotec Ltd. Launches Krill Oil Product - K•REAL® Gold	17-06-06	CI
Enzymotec Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	17-05-17	CI
Enzymotec Ltd. Announces Executive Changes, Effective April 18, 2017	17-03-09	CI
Enzymotec Ltd. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	17-02-22	CI
Enzymotec Ltd. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2016	17-02-06	CI
Enzymotec Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016; Provides Earnings Guidance for 2016	16-11-16	CI
Enzymotec Ltd. Announces to Depart Ariel Katz as President and Chief Executive Officer of the Company by the End of May 2017	16-11-16	CI
Enzymotec Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for the Full Fiscal Year 2016	16-08-09	CI
Enzymotec Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016	16-05-19	CI
Enzymotec Ltd. Reaffirms Earnings Guidance for the Fiscal 2016	16-05-19	CI
Enzymotec Seeks Acquisitions	16-05-19	CI
Enzymotec Ltd. Receives Patents in U.S. for Compositions and Processes Related to Infant Nutrition and China for INFAT	16-03-29	CI

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Sector

Commodity Chemicals

More about the company

Sector Other Commodity Chemicals

	1st Jan change	Capi.
AIR LIQUIDE	+3.69%	105B
SABIC	-6.59%	62.84B
PT CHANDRA ASRI PACIFIC TBK	+72.86%	49.15B
WANHUA CHEMICAL GROUP CO., LTD.	+15.33%	38.45B
LYONDELLBASELL INDUSTRIES N.V.	+5.32%	32.61B
WESTLAKE CORPORATION	+14.73%	20.65B
NINGXIA BAOFENG ENERGY GROUP CO., LTD.	+12.59%	16.81B
HENGLI PETROCHEMICAL CO.,LTD.	+18.15%	15.14B
RONGSHENG PETROCHEMICAL CO., LTD.	+3.29%	14.14B

Other Commodity Chemicals